AVRO - AVROBIO, Inc.
| Previous Close | 22.06 |
| Open | 22.45 |
| Bid | 22.61 x 900 |
| Ask | 22.79 x 1000 |
| Day's Range | 21.52 - 22.95 |
| 52 Week Range | 20.30 - 53.70 |
| Volume | 15,893 |
| Avg. Volume | 160,417 |
| Market Cap | 545.267M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.01 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.20 |
- GlobeNewswire•5 hours ago
Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•8 days ago
AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
“The third quarter has been productive for AVROBIO,” commented Geoff MacKay, President and Chief Executive Officer of AVROBIO. “In a recent clinical data update on AVR-RD-01, we were pleased with the α‑galactosidase A (AGA) enzyme activity demonstrated in patients with Fabry disease. In addition, we have achieved our first regulatory milestone for our gene therapy for Gaucher disease as it advances towards the clinic.
- GlobeNewswire•2 months ago
AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Oct. 04, 2018 -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare.
- GlobeNewswire•2 months ago
AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease
AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that it has received no objection to its clinical trial application (CTA) from Health Canada for a Phase 1/2 clinical trial of AVR-RD-02, the Company’s gene therapy for Gaucher disease. AVR‑RD-02 is an ex vivo lentiviral gene therapy.
- GlobeNewswire•2 months ago
AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease
First two patients in Phase 1 study continue to demonstrate AGA enzyme activity above the diagnostic range for classic Fabry disease 18 months and six months after receiving AVR-RD-01, respectively; Patient ...
- Benzinga•4 months ago
Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls
Avrobio Inc (NASDAQ: AVRO ), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million ...
- InvestorPlace•5 months ago
8 Biotech Stocks With IPOs This Week
This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.
